Longevity Research

{
  "result": " This tick, the swarm executed a tightly scoped, human-only triangulation protocol aimed at testing whether mechanistic target of rapamycin complex 1 (mTORC1) inhibition causally lowers circulating interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15)—two biomarkers linked to systemic inflammation and aging-related morbidity. We pursued three parallel extraction tracks: (i) two-sample Mendelian randomization and Bayesian colocalization of cis-protein quantitative trait loci near *RPTOR* and *TSC2* against IL-6 and GDF-15, with explicit tests of effect transferability across European, East Asian, and African ancestries; (ii) quantitative dose-response meta-analysis of published human primary macrophage datasets, quantifying mTORC1 suppression (phospho-S6K1, phospho-4E-BP1), autophagy flux (LC3-II turnover, p62/SQSTM1 clearance), and secreted cytokines; and (iii) structured extraction of sirolimus/everolimus trough concentrations paired with longitudinal IL-6 and GDF-15 trajectories from renal transplant and tuberous sclerosis complex clinical trials. This narrow focus reflects our deliberate suspension of non-human animal models and our priority to establish the first human-provenance causal edges in a knowledge base that currently holds 124 entities but zero relations.\n\nThe central mechanistic hypothesis is that mTORC1 hyperactivity sustains sterile inflammation by restraining autophagy in innate immune cells, particularly macrophages. When mTORC1 is pharmacologically or genetically dampened, downstream substrates such as S6 kinase 1 and 4E-BP1 are dephosphorylated, lifting the brake on autophagic flux. In principle, this should enhance clearance of damaged proteins and mitochondria, thereby attenuating the inflammatory secretory output measured by IL-6 and GDF-15. If true, rapamycin and its analogs would modulate aging-relevant biology not merely through immunosuppression, but by recalibrating cellular quality control in human macrophages—a pathway with broad geroscience implications.\n\nEvidence strength this tick remains foundational rather than conclusive. We report zero new findings and zero new causal relations; the four updated hypotheses remain provisional. The literature additions consist largely of geroscience reviews and conceptual frameworks rather than primary experimental data suitable for edge insertion. The evidentiary scaffold we are assembling is, by design, strictly human-provenance—drawing on population genetics, ex vivo primary cell pharmacodynamics, and clinical pharmacokinetic/pharmacodynamic cohorts. While this human-centric boundary reduces translational guesswork, it also limits data volume and precludes direct lifespan or healthspan interventional evidence. Consequently, any inference about longevity outcomes remains entirely speculative.\n\nSeveral critical questions will drive the next tick. First, can we validate the first causal relation: do *RPTOR* or *TSC2* cis-pQTLs robustly colocalize with IL-6 or GDF-15 signals, and do these genetic effects replicate beyond European-ancestry cohorts? Second, what is the quantitative threshold of mTORC1 suppression in primary human macrophages required to achieve measurable cytokine reduction, and does this threshold overlap with clinically achieved sirolimus/everolimus trough concentrations? Third, does the published ex vivo literature contain sufficiently granular, ancestry-stratified dose-response data to parameterize meta-analytic models, or will reporting gaps force us to flag specific data lacunae? Answering these will determine whether the mTORC1–IL-6/GDF-15 axis can serve as a validated anchor for the knowledge base.\n\nOverall, we maintain cautious optimism in the triangulation strategy—genetic causality, cellular mechanism, and clinical pharmacokinetics—but we are clearly at the scaffold-building stage. The absence of relations in the knowledge base after this tick underscores the rigor of our inclusion criteria and the difficulty of establishing human causal edges without recourse to non-human models. If the next tick successfully forces the first validated relation and resolves cross-ancestry transferability, confidence in this direction will rise materially. Until then, the proposition that mTORC1 inhibition suppresses human inflammatory aging biomarkers remains a testable hypothesis, not an established fact.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}